Adverse Event Reporting Requirements Can Be “Flexible,” FDA Says
Some FDA review divisions are reaching agreements that allow drug sponsors to submit less adverse event data to the agency
You may also be interested in...
Large simple safety studies should not become a routine pre-approval requirement, the Pharmaceutical Research & Manufacturers of America suggested during FDA's risk management public workshop April 9
FDA's proposed definition of "suspected adverse drug reactions" would encourage more premarketing adverse event reporting
HHS would be directed to harmonize FDA's clinical trial oversight regulations with the common rule under the Greenwood/DeGette human subject protection bill